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Background: In radiotherapy treatment planning, intravenous administration of an iodine-based contrast agent
during computed tomography (CT) improves the accuracy of delineating target volumes. However, increased tissue
attenuation resulting from the high atomic number of iodine may result in erroneous dose calculations because
the contrast agent is absent during the actual procedure. The purpose of this proof-of-concept study was to present
a novel framework to improve the accuracy of dose calculations using dual-energy virtual unenhanced CT in the
presence of an iodine-based contrast agent.
Methods: Simple phantom experiments were designed to assess the feasibility of the proposed concept. By
utilizing a “second-generation” dual-source CT scanner equipped with a tin filter for improved spectral separation,
four CT datasets were obtained using both a water phantom and an iodine phantom: “true unenhanced” images
with attenuation values of 2 ± 11 Hounsfield Units (HU), “enhanced” images with attenuation values of 274 ± 23 HU,
and two series of “virtual unenhanced” images synthesized from dual-energy scans of the iodine phantom, each
with a different combination of tube voltages. Two series of virtual unenhanced images demonstrated attenuation
values of 12 ± 29 HU (with 80 kVp/140 kVp) and 34 ± 10 HU (with 100 kVp/140 kVp) after removing the iodine
component from the contrast-enhanced images. Dose distributions of the single photon beams calculated from the
enhanced images and two series of virtual unenhanced images were compared to those from true unenhanced
images as a reference.
Results: The dose distributions obtained from both series of virtual unenhanced images were almost equivalent to
that from the true unenhanced images, whereas the dose distribution obtained from the enhanced images
indicated increased beam attenuation caused by the high attenuation characteristics of iodine. Compared to the
reference dose distribution from the true unenhanced images, the dose distribution pass rates from both series of
virtual unenhanced images were greater than 90%, while those from the enhanced images were less than
approximately 50–60%.
Conclusions: Dual-energy virtual unenhanced CT improves the accuracy of dose distributions in radiotherapy
treatment planning by removing the iodine component from contrast-enhanced images.
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The use of computed tomography (CT) is now an estab-
lished procedure in modern radiotherapy treatment
planning. Cross-sectional CT data allow for the accurate
delineation of surface contours and internal structures
including target and critical organs. In addition, the pixel
values, i.e., the CT numbers in Hounsfield Units (HU),
provide tissue electron density information, which allows
a pixel-by-pixel correction for tissue inhomogeneities
when calculating dose distributions. Although other im-
aging modalities are becoming important tools in treat-
ment planning, CT is still the fundamental and primary
modality.
An inherent disadvantage of CT is its relatively lower
contrast between lesions and surrounding tissue or ves-
sels. Thus, diagnostic CT often requires the intravenous
administration of an iodine-based contrast agent to en-
hance lesion-to-tissue contrast. Because the accurate
delineation of target volumes (and organs at risk) is cru-
cial in radiotherapy treatment planning, the use of an
iodine-based contrast agent is necessary in situations in
which contrast is likely to improve the accuracy of the
target or normal structure delineations. However, there
is a concern that the introduction of contrast agent may
result in erroneous dose calculations [1]. In an actual
treatment situation, the patient does not receive contrast
agent, and hence the tissue density during treatment will
differ from that during a contrast-enhanced CT scan. Al-
though several clinical studies on head and neck [2],
lung [3], and prostate cancers [4] have shown that con-
trast media had little influence on dose calculations, this
issue is still debated [5-7].
A recent advance in the field of CT was the introduc-
tion of dual-energy CT. Dual-energy CT acquires two
different datasets with different tube voltages (i.e., beam
energies). Within the range of photon energies in CT,
the CT numbers of soft tissues are almost independent
of beam energy. In contrast, CT numbers of high atomic
number materials such as iodine are noticeably energy-
dependent. Thus, materials with a high atomic number
can be further differentiated from soft tissues by apply-
ing different beam energies and analyzing the differences
in attenuation [8]. This principle allows clinicians to
reconstruct “virtual unenhanced” images from iodine
contrast-enhanced scans [9-15]. The attenuation differ-
ences of iodine between two energies can be utilized to
produce an “iodine map”, which can be subsequently
removed from images to create virtual unenhanced
images. Thus, virtual unenhanced images theoretically
provide CT numbers equivalent to those of true unen-
hanced images. It should be noted that the key to reliable
virtual unenhanced imaging lies on both the spectral sep-
aration between low- and high-energy beams, and low
image noise. These two fundamental requirements can beaccomplished by the “second generation” dual-source CT
scanner. The scanner utilizes two distinct X-ray sources
with corresponding detectors at an angle separation of
95°. The two sources can be simultaneously operated at
different tube voltages. Importantly, this feature has the
capability of applying an additional tin filter for a high-
energy beam. The filter is highly advantageous because it
narrows the spectrum, which results in higher dose effi-
ciency, less beam hardening, and improved spectral separ-
ation between the low- and high-energy beams [16,17].
The improved spectral separation allows for tube oper-
ation at a combined 100 kVp and 140 kVp rather than the
conventional dual-energy combination of 80 kVp and 140
kVp [17], and thus can reduce image noise. Furthermore,
iodine removal is more accurate with the filter than with-
out it when the subject adjoins a high attenuation material
(e.g. bone, contrast-enhanced large vessels, etc.) [13].
Using this promising technique under iodine contrast
enhancement, we propose a novel strategy for improved
radiation treatment planning. In this scheme, dose calcu-
lations can be performed using synthesized virtual
unenhanced CT images, while the delineation of the tar-
get and critical organs can be conducted using the original
contrast-enhanced CT images (Figure 1). The purpose of
this preliminary study was to investigate the feasibility of
our proposed scheme in simple phantom experiments
using the second-generation dual-source CT scanner.
Methods
This study comprised two phantom experiments. The
first experiment assessed dual-energy virtual unenhanced
attenuation values of iodine solutions under two different
combinations of tube voltages. The second experiment
investigated the feasibility of dose calculation using virtual
unenhanced imaging. All experiments were conducted
using a dual-source CT scanner (SOMATOM Definition
Flash, Siemens AG, Erlangen, Germany). A dedicated ap-
plication “Liver VNC” (Siemens) was utilized to recon-
struct virtual unenhanced images.
Assessment of virtual unenhanced attenuation values
We prepared a phantom comprising eight polypropylene
syringes, each containing a 10-mL mixture of water and
an iodine-based contrast agent (Iopamidol, 300 mgI/mL)
at different dilutions (4.50%, 2.00%, 1.00%, 0.50%, 0.25%,
0.13%, 0.06%, and 0.00% by weight). The phantom was
placed at the isocenter of the CT scanner, and scanned
using both single-energy and dual-energy helical modes.
For the single-energy scan, only one X-ray tube was op-
erated at 120 kVp and 100 mAs. For the dual-energy
scan, two combinations of tube settings, each using the
tin filter for the high-energy beam, were tested: (i) 80
kVp with 100 mAs and 140 kVp with 39 mAs (referred
to as the “80/Sn140-kVp protocol”); and (ii) 100 kVp
Contrast-enhanced CT





Figure 1 Schematic of the proposed concept. Dose calculations can be performed using synthesized virtual unenhanced CT images, while the
delineation of the target and critical organs can be conducted using the original contrast-enhanced CT images.
Yamada et al. Radiation Oncology 2014, 9:168 Page 3 of 10
http://www.ro-journal.com/content/9/1/168with 100 mAs and 140 kVp with 77 mAs (referred to as
the “100/Sn140-kVp protocol”). The slice thickness and
reconstructed field-of-view for both scans were 5 mm
and 150 mm, respectively. The images were reconstructed
with standard body kernels (B35f for single-energy scans
and D26f for dual-energy scans). Two series of virtual
unenhanced images (i.e., 80/Sn140-kVp and 100/Sn140-
kVp protocols) were synthesized from the corresponding
dual-energy data. In addition, “mixed” images were syn-
thesized using a linear weighting of the low- and high-kVp
images. In diagnostic dual-energy applications, the mixed
images are used as representative of dual-energy data, be-
cause they are similar to traditional single-energy (i.e., 120
kVp) images. Circular regions-of-interest (ROIs) were po-
sitioned within the syringes to obtain mean attenuation
values in HU. The size of the ROIs was chosen to encom-
pass an approximately 80% area of the syringes. The scans
were repeated three times, and the mean attenuation
values and standard deviation of the three measurements
were calculated for comparisons.
Feasibility of dose calculation using virtual unenhanced CT
Because this was a pilot study, a simple phantom experi-
ment was designed to assess the feasibility of dose calcula-
tions on virtual unenhanced CT images. Two polypropylene
containers (250 mm width, 175 mm height, and 350 mm
depth) filled either with distilled water (referred to as the
“water phantom”) or diluted (3%) Iopamidol contrast
agent (referred to as the “iodine phantom”) were prepared
and imaged to generate four CT datasets. First, the water
phantom was scanned in single-energy mode, provid-
ing the “true unenhanced” images. Second, the iodine
phantom was scanned in single-energy mode, providing
the “enhanced” images. Third, the iodine phantom was
scanned in dual-energy mode with the 80/Sn140-kVp
protocol, providing the “virtual unenhanced (80/Sn140-
kVp)” images. Finally, the iodine phantom was scanned in
dual-energy mode with the 100/Sn140-kVp protocol, pro-
viding the “virtual unenhanced (100/Sn140-kVp)” images.
Each phantom was positioned on the patient table and
scanned at the isocenter of the CT scanner. The imagingparameters were the same as those described above, ex-
cept that the slice thickness was 2.5 mm and the displayed
field-of-view was 330 mm.
Attenuation values of the phantoms depicted in the
four datasets were measured using ROI analysis at the
central slice. The mean and standard deviation of the at-
tenuation values for each image were obtained from a
rectangular ROI positioned to encompass greater than
an 80% area of the phantom, but inside the outer edges.
Furthermore, attenuation profiles passing from the top
to the bottom of the phantom were obtained (adjacent
ten profile curves were measured and then averaged to
reduce fluctuations due to noise) to evaluate attenuation
values outside the ROI (especially at the bottom of the
phantom where iodine sedimentation is likely to occur),
although we took care to uniformly dilute the contrast
agent during preparation of the iodine phantom. Figure 2
shows a photograph of the phantom and its corresponding
CT images, detailing both the ROI setting for attenu-
ation measurements and the reference line for profile
curve measurements.
These four CT datasets were transferred to a Pinnacle3
treatment planning system (version 8.0 m; Philips, Madison,
WI, USA) for dose calculations. The dose distribution of a
single photon beam from a Siemens Oncor Impression
Plus system was calculated using a collapsed cone convo-
lution algorithm with a dose grid size of 2 mm. Two beam
energies (4 MV and 10 MV) and two field sizes (4 × 4 cm2
and 10 × 10 cm2) were tested for each dataset. The beam
was planned to deliver 100 monitor units at a 10-cm
depth at the center of the phantom. Although the phan-
tom was carefully prepared, it was impossible to avoid
introducing small air bubbles at the top of the phantom.
Therefore, the posterior field was chosen to minimize the
effects of these small bubbles on the dose calculations.
The dose distributions obtained from the enhanced and
virtual unenhanced (both the 80/Sn140-kVp and 100/
Sn140-kVp protocols) images were quantitatively com-
pared to those from the true unenhanced images using
MapCHECK (Sun Nuclear, Melbourne, FL, USA) analysis
software. For the analysis, the calculated planar dose
(b)(a)
Figure 2 The phantom used in the second experiment. Photograph (a) and CT image (b) of the polypropylene container. The purple rectangle
and blue arrow in (b) illustrate the region of interest for attenuation measurements and position of attenuation profile measurements, respectively.
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was imported into the software; the distribution obtained
from the true unenhanced images was used as a reference,
and the remaining three were the subjects being tested.
The assessment was performed based on the percent-
dose-difference and distance-to-agreement at a 10% dose
threshold. A set of acceptance criteria (2% and 2 mm) sat-
isfying the guideline [18] was used, and the percentage of
points passing the acceptance criteria was evaluated.
Results
Figure 3 shows the results of attenuation measurements
for the iodine syringes on the single-energy, and the
dual-energy (100/Sn140-kVp protocol) mixed and virtual
unenhanced images. The exact attenuation values includ-
ing both the 80/Sn140-kVp and 100/Sn140-kVp protocols





















Figure 3 Attenuation measurements of iodine solutions at
different iodine concentrations. Single-energy images were ac-
quired at a tube voltage of 120 kVp. Mixed images and virtual unen-
hanced images were synthesized from dual-energy (100 kVp and
140 kVp with a tin filter) data.tested in this experiment provided attenuation values up to
approximately 440 HU under the single-energy scan. The
virtual unenhanced attenuation values using this range of
iodine concentrations were reasonably stable and were
close to both the single-energy and dual-energy mixed at-
tenuation values at a 0% iodine concentration.
Figure 4 shows representative (a) true unenhanced, (b)
enhanced, (c) virtual unenhanced (80/Sn140-kVp), and
(d) virtual unenhanced (100/Sn140-kVp) images of the
phantom. All the CT images were displayed at fixed win-
dow settings (window level, 50 HU; window width, 600
HU), allowing us to compare the image contrast between
the four images, visualize the effect of tube voltage settings
on virtual unenhanced images (c and d), and visually con-
firm the presence or absence of iodine sedimentation (b).
The virtual unenhanced image with the 80/Sn140-kVp
protocol showed higher image noise and dark-band artifact,
while the image obtained with the 100/Sn140-kVp protocol
showed more uniform attenuation and less image noise.
No obvious iodine sedimentation was found in the en-
hanced image (b). Figure 5 shows the attenuation profiles
of the phantom. The profile from the enhanced image
(red line) indicates that the iodine was almost uniformly
distributed inside the phantom because the profile is al-
most flat, although the profile was slightly cupped due to
beam hardening. The attenuation values of the phantoms
depicted in the true unenhanced, enhanced, and virtual
unenhanced images are listed in Table 2. The mean at-
tenuation values of the iodine phantom on the virtual
unenhanced images were lower (11.6 ± 29.2 HU with the
80/Sn140-kVp protocol and 34.1 ± 9.9 HU with the 100/
Sn140-kVp protocol) than those on the enhanced image
(274.3 ± 22.5 HU).
Figures 6, 7 and 8 compare the four representative planar
dose distributions (a–d), planned at beam energies of ei-
ther 10 MV (Figure 6) or 4 MV (Figures 7 and 8), and field
sizes of either 10 × 10 cm2 (Figures 6 and 7) or 4 × 4 cm2
(Figure 8), obtained from the true unenhanced, enhanced,






Dual-energy (80 kVp/Sn140 kVp) Dual-energy (100 kVp/Sn140 kVp)
Mixed Virtual unenhanced Mixed Virtual unenhanced
0.00 −11.3 ± 1.3 −10.4 ± 0.1 −23.0 ± 1.0 −10.7 ± 0.6 −21.0 ± 0.6
0.06 −3.9 ± 0.5 −6.9 ± 0.1 −26.8 ± 0.9 −8.0 ± 0.4 −24.5 ± 1.5
0.13 4.7 ± 0.5 0.1 ± 0.2 −25.1 ± 0.8 −1.6 ± 0.4 −24.1 ± 0.7
0.25 16.4 ± 0.4 11.1 ± 1.1 −26.6 ± 1.8 7.9 ± 0.8 −25.3 ± 1.1
0.50 40.5 ± 0.5 33.5 ± 0.2 −25.8 ± 1.1 27.2 ± 0.4 −25.7 ± 1.1
1.00 91.1 ± 0.4 78.5 ± 0.4 −27.1 ± 1.1 65.8 ± 0.6 −28.4 ± 0.4
2.00 192.3 ± 0.3 168.7 ± 0.3 −29.1 ± 0.3 143.0 ± 0.3 −32.5 ± 1.3
4.50 444.1 ± 0.7 397.9 ± 0.4 −28.7 ± 0.3 340.1 ± 0.3 −35.1 ± 1.9
Note: Attenuation values are mean ± standard deviation from three measurements.
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Sn140-kVp protocols) CT images. The dose difference
(i.e. error) maps derived between the tested (enhanced
or virtual unenhanced) and reference (true unenhanced)
dose distributions are also shown (e–g). In each condition
(Figures 6, 7 and 8), the dose distributions obtained from
both the virtual unenhanced images were quite similar to(a) True unenhanced
(c) Virtual unenhanced 
(80/Sn140-kVp)
Figure 4 Representative CT images of the phantom for dose calculati
phantom. Remaining enhanced images (b), virtual unenhanced (80/Sn140-
(d) were obtained using the iodine phantom. The enhanced image (b) sho
sedimentation. The virtual unenhanced image obtained using the 80/Sn14
while the image using the 100/Sn140-kVp protocol provided adequate imathat generated from the true unenhanced images, whereas
the dose distribution obtained from the enhanced image
indicated increased beam attenuation. Using the enhanced
images, errors in dose calculations increased as the beam
passed from the bottom to the top of the iodine phantom.
In contrast, the errors were almost entirely 0 cGy when
the virtual unenhanced images, especially the 100/Sn140-(b) Enhanced
(d) Virtual unenhanced 
(100/Sn140-kVp)
ons. True unenhanced images (a) were obtained using the water
kVp) images (c), and virtual unenhanced (100/Sn140-kVp) images
ws almost uniform attenuation, indicating no obvious iodine























↑ Top of the phantom Bottom of the phantom ↑
Position
Figure 5 Attenuation profiles. Attenuation values in HU are
plotted against the pixel locations (shown in Figure 2b). The
profile from the enhanced image (red line) shows almost uniform
distribution of attenuation values with a slight cupping due to beam
hardening, indicating no obvious iodine sedimentation. The
profile from the virtual unenhanced images using the 100/Sn140-kVp
protocol is quite stable, while the profile using the 80/Sn140-kVp
protocol was highly fluctuated by dark-band artifacts.
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of the dose calculations based on the virtual unenhanced
and enhanced images. When the virtual unenhanced im-
ages were utilized for dose calculations, pass rates greater
than 90% were achieved, while the pass rates were less
than approximately 50–60% when enhanced images were
used.
Discussion
The use of a contrast agent during CT for treatment
planning offers the potential benefit of a much higher
accuracy in delineating target and critical volumes. How-
ever, there is a significant concern that the high atomic
number of iodine may introduce errors into dose calcu-
lations; the calculated dose may be underestimated,
resulting in the delivery of a higher dose than prescribed.
This scenario would occur in organs containing an in-
creased iodine concentration. In fact, Shibamoto et al.
found that the administration of a contrast agent influencedTable 2 Attenuation measurements of water and iodine
phantoms
Measurements Attenuation values [HU]
Water phantom/true unenhanced image 1.6±11.0







Note: Attenuation values are mean ± standard deviation in the region
of interest.treatment planning at the upper abdomen, especially
when the beams passed through organs with high iodine
concentrations such as the liver, spleen, and kidneys [5].
Our present results support their findings. The iodine
phantom used in this study presented almost uniformly
distributed attenuation values of approximately 270 HU
(Figure 4b; Figure 5; Table 2), which approximates that of
organs in the upper abdomen on contrast-enhanced CT.
As shown in Figures 6, 7 and 8(b), the dose distributions
obtained from the enhanced images show increased beam
attenuation compared to those from the true unenhanced
images (a). The corresponding error maps (Figures 6, 7
and 8e) show that the calculated dose obtained from the
enhanced images tends to differ from that based on the
true unenhanced images as the beam passes through the
phantom from the bottom to the top. In Figure 7, for in-
stance, the dose distribution (a) obtained using the true
unenhanced images shows a delivery of 72 cGy at the 10-
cm depth of the central axis; in contrast, the dose error
was at least 4 cGy when the enhanced images were used
(e). In this case, the use of the enhanced images leads to
erroneous dose delivery greater than 5% of the prescribed
dose. This error is not negligible and would be problem-
atic for treatment planning, especially in the upper abdo-
men as Shibamoto et al. reported [5].
Our novel approach to solve this issue is to remove
the iodine component from contrast-enhanced CT using
dual-energy virtual unenhanced imaging. Dual-energy vir-
tual unenhanced imaging has recently become a promis-
ing technique in diagnostic CT to reduce the radiation
dose by negating the need for an unenhanced scan [9-11].
Although the clinical potential of dual-energy CT in the
field of radiation oncology has not been well investigated
to date, several studies have shown that dual-energy CT
allows for an accurate estimation of electron density for
treatment planning [19-21]. Our study reveals an add-
itional important aspect of its application that could im-
prove the accuracy of radiotherapy treatment planning.
Figure 3 shows that virtual unenhanced CT can remove
the iodine component from a contrast-enhanced CT
image within a wide range of iodine concentrations at CT
number levels greater than the water density, in accord-
ance with previous reports [9-14], including a similar
phantom study of iodine solutions [10]. Thus, our study
aimed to improve the accuracy of dose calculations from
contrast-enhanced CT by removing their iodine compo-
nents, and the results successfully demonstrated the feasi-
bility of our proposed method. As shown in Figures 6, 7
and 8, the dose distributions obtained from virtual unen-
hanced images (c and d) were almost equivalent to those
from true unenhanced images (a). The differences in dose
calculations between true unenhanced and virtual unen-
hanced images were extremely close to 0 cGy (f and g), ex-


















































72 cGy72 cGy 72 cGy 72 cGy
(a) True unenhanced (b) Enhanced (c) Virtual unenhanced
(80 / Sn140 kVp)
(d) Virtual unenhanced
(100 / Sn140 kVp)
(e) Error in (b) (f) Error in (c) (g) Error in (d)
60 cGy
Figure 6 Planar dose distributions and error maps (energy, 10 MV; field size, 10 × 10 cm2). Dose calculations were performed using
(a) true unenhanced, (b) enhanced, (c) virtual unenhanced (80/Sn140-kVp), and (d) virtual unenhanced (100/Sn140-kVp) images. The three
error (difference) maps correspond to the (e) enhanced, (f) virtual unenhanced (80/Sn140-kVp), and (g) virtual unenhanced (100/Sn140-kVp)
images, with the true unenhanced images as the reference. Dose distributions obtained from the virtual unenhanced images are quite similar to dose
distributions from the true unenhanced images. In particular, the virtual unenhanced (100/Sn140-kVp) images achieved almost entirely 0-cGy of errors,
except at the beam edges.
Yamada et al. Radiation Oncology 2014, 9:168 Page 7 of 10
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gradients. In addition, the use of the 100/Sn140-kVp
protocol further improved the accuracy of dose distribu-
tions at the dose build-up region. The pass rates of dose
calculations (Table 3) from the virtual unenhanced images
were greater than 90%, whereas those from the enhanced
images were less than approximately 50–60% and thus no
longer acceptable.
The virtual unenhanced imaging results in potentially un-
stable CT numbers when the differences between attenu-
ation values at low- and high-kVp are small. Therefore, the
“first-generation” dual-source CT scanner minimized spec-
tral overlap by performing the low-energy scan at 80 kVp
[8]. However, the use of an 80-kVp beam brought about an
inappropriately low photon rate at the detectors, especially
in the abdominal scan, due to a low penetration. Thus, the
resultant virtual unenhanced images suffered from in-
creased image noise and artifacts. Although the tin filter
could improve spectral separation, the use of an 80-kVpbeam would still be problematic. The virtual unenhanced
attenuation values of iodine syringes with the 80/Sn140-
kVp protocol were indeed more stable than those obtained
with the 100/Sn140-kVp protocol at high iodine concentra-
tions (Table 1); this experiment was performed with a small
phantom. In fact, the virtual unenhanced (80/Sn140-kVp)
images of the iodine phantom, which was used in the
second experiment, suffer from increased noise and dark-
band artifacts (Figure 4,c). The attenuation profile with
the 80/Sn140-kVp protocol (Figure 5, green line) fluc-
tuated greatly at the center of the phantom, due to the
dark-band artifacts. In contrast, the virtual unenhanced
attenuation values using the 100/Sn140-kVp protocol
were stable qualitatively (Figure 4d) and quantitatively
(Figure 5, blue line). The mean attenuation values of the
virtual unenhanced (100/Sn140-kVp) and true unenhanced
images were 34.1 ± 9.9 HU and 1.6 ± 11.0 HU, respectively.
This small difference had no effect on dose calculations as


















































48 cGy72 cGy 72 cGy 72 cGy72 cGy
(a) True unenhanced (b) Enhanced (c) Virtual unenhanced
(80 / Sn140 kVp)
(d) Virtual unenhanced
(100 / Sn140 kVp)
(e) Error in (b) (f) Error in (c) (g) Error in (d)
Figure 7 Planar dose distributions and error maps (energy, 4 MV; field size, 10 × 10 cm2). Dose calculations were performed using (a) true
unenhanced, (b) enhanced, (c) virtual unenhanced (80/Sn140-kVp), and (d) virtual unenhanced (100/Sn140-kVp) images. The three error
(difference) maps correspond to (e) enhanced, (f) virtual unenhanced (80/Sn140-kVp), and (g) virtual unenhanced (100/Sn140-kVp) images,
with the true unenhanced images as the reference. In addition to findings similar to those in Figure 6, more prominent dose errors are
elicited using the enhanced images (e).
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http://www.ro-journal.com/content/9/1/168The current dual-source virtual unenhanced CT has sev-
eral known potential limitations, which were investigated
by Barrett, et al. [9]. For radiotherapy treatment planning,
its relatively smaller field-of-view and susceptibility to
motion warrants consideration. The effective field-of-
view that can remove iodine components from contrast-
enhanced images is limited to 322 mm or less in diameter.
This is problematic in larger patients or in more superfi-
cial radiotherapy targets because the contrast-enhanced
tissue that is located outside the region will remain “en-
hanced” after the iodine-removal process. This limitation
arises from the current scanner configuration, and there-
fore, it can be alleviated in the future. Also notable is the
relatively higher susceptibility to motion in virtual unen-
hanced imaging, which arises from the 95° offset of the
source-detector systems. The angle offset causes one de-
tector to see a different motion compared to the other
detector, and this difference is amplified by the subtraction
process. A shorter gantry rotation time can reduce motion
artifacts, but the potential for the artifact remains,
particularly in the upper-abdominal organs, lung bases,and cardiovascular systems. Another potential limitation
of virtual unenhanced imaging is the underestimation
of attenuation values of high atomic number materials
such as bone. In previous reports [9-11,14], clinical
virtual unenhanced images visually demonstrated highly
attenuating bone, resembling the normal CT appear-
ance; the iodine removal process would affect the vir-
tual unenhanced attenuation value, depending on the
parameters of iodine removal (e.g., “standard tissue” and
“fat” CT numbers, “beam-hardening correction” option
for iodine, and “relative contrast enhancement ratio” value
between low- and high-energy images in “Liver VNC”
application). We expect that this underestimation of
bone attenuation has little influence on the dose cal-
culation because bone (especially cortical bone) en-
compasses a relatively small volume within the trunk;
however, further investigations evaluating the accuracy
and the impact of bone virtual unenhanced attenuation
values on dose calculations, optimizing the processing



























































(a) True unenhanced (b) Enhanced (c) Virtual unenhanced
(80 / Sn140 kVp)
(d) Virtual unenhanced
(100 / Sn140 kVp)
(e) Error in (b) (f) Error in (c) (g) Error in (d)
Figure 8 Planar dose distributions and error maps (energy, 4 MV; field size, 4 × 4 cm2). Dose calculations were performed using (a) true
unenhanced, (b) enhanced, (c) virtual unenhanced (80/Sn140-kVp), and (d) virtual unenhanced (100/Sn140-kVp) images. The three error
(difference) maps correspond to (e) enhanced, (f) virtual unenhanced (80/Sn140-kVp), and (g) virtual unenhanced (100/Sn140-kVp) images, with
the true unenhanced images as the reference. Findings similar to those in Figures 6 and 7 were observed.
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therefore has several limitations. First, we only conducted
simple phantom experiments and did not perform any
clinical investigations. Second, the optimal acquisition and
reconstruction parameters suitable for applying virtual
unenhanced images to radiotherapy treatment planning
were not investigated. These limitations are practical in
nature; the dual-energy CT scanner used in this study is
currently not available for radiotherapy treatment plan-
ning. Third, as mentioned above, the reliability of virtual
unenhanced attenuation values of high atomic numberTable 3 Pass rates of dose calculations based on the enhance
Energy [MV] Field size [cm2]
Enhance
10 10 × 10 45.6
10 4 × 4 59.3
4 10 × 10 37.1
4 4 × 4 44.9materials such as bone has not been investigated. Further
investigation of these issues is needed to confirm the clin-
ical potential of virtual unenhanced CT in radiotherapy
treatment planning.
Conclusions
We have proposed a novel strategy to improve the accuracy
of radiotherapy treatment planning using dual-energy vir-
tual unenhanced CT. The introduction of contrast agents
can improve the delineation of the target and risk organs.
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http://www.ro-journal.com/content/9/1/168contrast-enhanced CT images to provide virtual unen-
hanced images to perform more accurate dose calculations.
Our results have successfully provided the first proof-of-
concept.
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